Deborah Dunsire after three years at Lundbeck: "We're coming up to an inflection point in neuroscience"
Before she took on the role, Deborah Dunsire knew perfectly well that drug development within neurology and psychiatry comes with its own unique challenges compared to cancer, an area in which she has spent the majority of her career. Improvements for brain disorders are on the way, but the road ahead is long, says the CEO at Lundbeck.
by ELIZABETH MØNSTED JOHANSEN, translated by Daniel Pedersen
In many ways, it was a journey back in time for Deborah Dunsire when she took the job as CEO at Lundbeck. This is not to say Denmark's life sciences industry is lagging behind the US. Rather, it has something to do specifically with the disease area with which she is now working.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck chairman demands change: "We can't live with this"
For subscribers
New Lundbeck candidate to kick off R&D division
For subscribers
